Kobo Biotech Ltd
- Market Cap ₹ 5.46 Cr.
- Current Price ₹ 2.29
- High / Low ₹ 4.56 / 1.99
- Stock P/E
- Book Value ₹ 23.6
- Dividend Yield 0.00 %
- ROCE -4.43 %
- ROE -65.6 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.10 times its book value
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -27.2% over last 3 years.
- Company has high debtors of 671 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|
| 162 | 287 | 404 | 103 | 103 | |
| 133 | 238 | 361 | 104 | 104 | |
| Operating Profit | 29 | 49 | 43 | -1 | -1 |
| OPM % | 18% | 17% | 11% | -1% | -1% |
| 0 | 0 | 0 | 0 | 0 | |
| Interest | 13 | 21 | 18 | 24 | 24 |
| Depreciation | 6 | 11 | 10 | 10 | 10 |
| Profit before tax | 10 | 18 | 15 | -34 | -34 |
| Tax % | 0% | 11% | 8% | 2% | 2% |
| 10 | 16 | 14 | -35 | -35 | |
| EPS in Rs | 4.37 | 6.72 | 6.22 | -15.48 | -15.48 |
| Dividend Payout % | 23% | 15% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -29% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -26% |
| 5 Years: | -24% |
| 3 Years: | -13% |
| 1 Year: | -39% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -27% |
| Last Year: | -66% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 |
| Reserves | 39 | 51 | 65 | 31 | 31 |
| 131 | 118 | 182 | 179 | 179 | |
| 57 | 154 | 142 | 163 | 163 | |
| Total Liabilities | 250 | 346 | 412 | 396 | 396 |
| 110 | 100 | 108 | 104 | 104 | |
| CWIP | 0 | 13 | 3 | 2 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 140 | 232 | 301 | 290 | 290 | |
| Total Assets | 250 | 346 | 412 | 396 | 396 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|
| 64 | 37 | 7 | 7 | ||
| -14 | -7 | -5 | -5 | ||
| -27 | -38 | -13 | -13 | ||
| Net Cash Flow | 23 | -9 | -11 | -11 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | |
|---|---|---|---|---|---|
| Debtor Days | 143 | 187 | 185 | 671 | 671 |
| Inventory Days | 179 | 79 | 66 | 300 | 300 |
| Days Payable | 115 | 203 | 111 | 468 | 468 |
| Cash Conversion Cycle | 207 | 62 | 140 | 503 | 503 |
| Working Capital Days | 88 | 28 | 25 | 98 | 73 |
| ROCE % | 20% | 14% | -4% | -4% |
Documents
Announcements
-
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
30 Oct - 15th CoC meeting held 01-Oct-2025; voting 03–08 Oct 2025 on draft RFRP.
-
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
30 Oct - CoC approved 90-day CIRP extension to 29.01.2026; RFRP issued; ₹72,55,430 GST claim included.
-
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
30 Oct - 14th CoC meeting held 25 Aug 2025; voting 27–28 Aug; JM Financial ARC 99.12%.
-
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
30 Oct - CoC approved 90-day CIRP extension to 28.11.2025; forfeited Rs1.05 crore; invite EoIs with Rs5 lakh EMD.
-
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
30 Oct - Thirteenth CoC meeting held Aug 4, 2025; draft minutes circulated Aug 6; voting Aug 6–11, 2025.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1]
KBL manufactures Active Pharmaceutical Ingredients based on Fermentation technology. Its manufacturing facility is located in Solapur, Maharashtra, spread over 21 acres